Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer
2019 ◽
Vol 62
(9)
◽
pp. 4716-4730
◽
2013 ◽
2015 ◽
Keyword(s):
2014 ◽
Vol 32
(15_suppl)
◽
pp. e16080-e16080
2009 ◽
Vol 69
(7)
◽
pp. 2912-2918
◽
2014 ◽
Vol 32
(15_suppl)
◽
pp. 11013-11013
◽